Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures

We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, during 28 weeks of therapy (Tsibris AM et al., J. Virol. 82:8210–8214, 2008). To investigate the decay of VCV resistance mutations, a standard clonal analysis of ful...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Tsibris, Athe M. N., Hu, Zixin, Paredes, Roger, Leopold, Kay E., Putcharoen, Opass, Schure, Allison L., Mazur, Natalie, Coakley, Eoin, Su, Zhaohui, Gulick, Roy M., Kuritzkes, Daniel R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2012
Aiheet:
Virus-Cell Interactions
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3393533/
https://ncbi.nlm.nih.gov/pubmed/22491471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00286-12
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia